title: Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
abstract: BACKGROUND
  In patients with non-small-cell lung cancer (NSCLC), the effects of second-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies. Therefore, using individual-level data, we aimed to determine the relationships between progression-free survival (PFS) and post-progression survival (PPS) with OS in patients with advanced NSCLC treated with docetaxel monotherapy as second-line chemotherapy.
  
  
  METHODS
  Between April 2002 and December 2014, data from 86 patients with advanced NSCLC who underwent second-line docetaxel monotherapy following first-line treatment with platinum combination chemotherapy were analyzed. The relationships of PFS and PPS with OS were analyzed at the individual level.
  
  
  RESULTS
  Spearman rank correlation and linear regression analyses showed that PPS was strongly associated with OS (r = 0.86, p < 0.05, R2 = 0.93), whereas PFS was moderately correlated with OS (r = 0.50, p < 0.05, R2 = 0.21). Performance status at the end of second-line treatment and the number of regimens after progression beyond second-line chemotherapy were significantly associated with PPS (p < 0.05).
  
  
  CONCLUSIONS
  In patients with advanced NSCLC with unknown oncogenic driver mutations undergoing docetaxel monotherapy as second-line chemotherapy, when compared with PFS, PPS had a stronger association with OS. This finding suggests that subsequent treatment after disease progression following second-line docetaxel monotherapy has a significant influence on OS.
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan.
authors.forename: Mie
authors.initials: M
authors.lastname: Kotake
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Miura
authors.forename: Hisao
authors.initials: H
authors.lastname: Imai
authors.forename: Keita
authors.initials: K
authors.lastname: Mori
authors.forename: Reiko
authors.initials: R
authors.lastname: Sakurai
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Tomizawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Minato
authors.forename: Ryusei
authors.initials: R
authors.lastname: Saito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hisada
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010984:Platinum / Q000737:chemistry / Q000627:therapeutic use; D016016:Proportional Hazards Models; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D010984:Platinum
keywords: Docetaxel; Non-small-cell lung cancer; Overall survival; Post-progression survival; Progression-free survival; Second-line chemotherapy